The demands for fast dissolving tablets have received ever increasing day by day during the last two decade. In the proposed present project study, the effect of natural Superdisintegrants was compared with synthetic Super disintegrants and conventional Super disintegrants in the of fast dissolving tablet formulation of Etoricoxib. Etoricoxib NSAID is used for the treatment of mild to moderate pain in various conditions like (osteoarthritis) and reducing pain, swelling, and joint stiffness caused with rheumatoid arthritis. In the present work 9 formulations of FDT (Fast dissolving tablet) of Etoricoxib were prepared by using Super disintegrants was evaluated and compiles with the official parameters and specifications. Various formulations were prepared using four different superdisintegrsnts namely natural superdisintegrats Fenugreek Powder, sodium starch glycolate, cross carmelose sodium with three concentrations (4%, 8%, 12%) by direct compression method. Formulation F2 showed the lowest disintegration time and in-vitro dissolution studies recorded that formulation F2 showed 99.55% drug release at the end of 3 minutes. The best formulations among these were also found to be stable and optimized formulations were subjected to the stability studies as per ICH guideline.

Background: Anemia reported during pregnancy is a burdensome public health problem all around the world, problem is vast among developing¬ countries. Women during pregnancy are more prone for developing anemia not only because of increased iron demand and its poor bioavailability along with hemodilution physiological increase in plasma volume (physiological increase in plasma volume) which acts synergistically. Material & Methods: The present study was conducted at the Department of Community Medicine of our medical college over a duration of six months, from June 2020 to December 2020. A sample size of 400 pregnant women was determined using the Epi Info software version 7.2, with a 95% confidence interval and a 10% acceptable margin of error. Results: The findings of the present study reveal notable differences in the burden of anemia among pregnant women, categorized based on their primigravida status and birth intervals. Among primigravida, the majority (54.6%) exhibited no anemia, followed by mild (33.3%) and moderate (12%) cases, with no instances of severe anemia observed. Conversely, among women with birth intervals of less than two years, there were no cases of no anemia, with the prevalence of mild, moderate, and severe anemia standing at 45.6%, 41.4%, and 13%, respectively. Similarly, among those with birth intervals of more than two years, no instances of no anemia were reported, with 34.8%, 63.1%, and 2.2% experiencing mild, moderate, and severe anemia, respectively. These variations in the burden of anemia across different groups were found to be statistically highly significant (p value < 0.001). Conclusions: The study underscores the significant prevalence and impact of anemia, particularly highlighting the elevated risk among rural populations. Moreover, it reveals a noteworthy association between anemia and birth interval, with a higher burden of severe anemia observed among pregnant women with birth intervals of less than two years.

Background: Preeclampsia and eclampsia are major hypertensive disorders of pregnancy associated with significant maternal and perinatal morbidity and mortality. Endothelial dysfunction, tissue ischemia, and cellular injury in these conditions result in elevated serum lactate dehydrogenase (LDH) levels. The present study aimed to evaluate serum LDH as an early diagnostic biomarker in preeclampsia and eclampsia and to assess its association with disease severity and maternal–fetal outcomes. Methods: This hospital-based observational study included 167 pregnant women divided into three groups: normotensive controls (n=56), preeclampsia (n=56), and eclampsia (n=55). Detailed clinical evaluation and laboratory investigations were performed in all participants. Serum LDH estimation was carried out using automated biochemical analysis. Maternal complications, fetal outcomes, and correlation of LDH with clinical and biochemical parameters were assessed. Statistical analysis was performed using SPSS software, and p<0.05 was considered statistically significant. Results: Mean serum LDH levels were significantly higher in preeclampsia (691.8 ± 188.6 U/L) and eclampsia (1184.6 ± 346.7 U/L) compared to normotensive women (382.5 ± 96.4 U/L) (p<0.001). Elevated LDH levels were significantly associated with severe hypertension, thrombocytopenia, elevated liver enzymes, renal dysfunction, HELLP syndrome, and ICU admission (p<0.001). Adverse fetal outcomes including preterm delivery, low birth weight, NICU admission, fetal distress, and perinatal mortality were significantly more common among women with elevated LDH levels. Serum LDH showed significant positive correlation with systolic blood pressure (r=0.71), diastolic blood pressure (r=0.68), serum uric acid (r=0.62), and serum creatinine (r=0.58), while negative correlation was observed with platelet count, gestational age at delivery, and birth weight (p<0.001). Conclusion: Serum LDH is a reliable and cost-effective biomarker for early diagnosis and severity assessment of preeclampsia and eclampsia. Elevated LDH levels are strongly associated with maternal complications and adverse perinatal outcomes, making LDH a useful tool for early risk stratification and timely clinical intervention in hypertensive disorders of pregnancy.